Two announcements made by FDA in late October signal a marked change to FDA’s regulatory approach to “homeopathic” drugs. On October 25, 2019, FDA withdrew the 1988 Compliance Policy Guide (“CPG”) 400.400 Conditions Under Which Homeopathic Drugs May Be Marketed, and, concurrently, published revised draft guidance titled Drug Products Labeled as Homeopathic (the “Revised Homeopathic Draft Guidance”).
Homeopathy—an alternative medical approach that began in the late 18th century—is based on the belief that (1) a substance that causes symptoms in a healthy ...
Blog Editors
Recent Updates
- The First National Health Care Fraud Takedown of the Second Trump Administration: What Stayed the Same and What Is New?
- Latest Moves by Federal Agencies Regarding Gender-Affirming Care: Risks Mount for Providers
- Lone Star AI: How Texas Is Pioneering President Trump’s Tech Agenda
- New OIG Advisory Opinion Approves Manufacturer’s Warranty for Injuries Caused by Medical Device
- DOJ, HHS Announce Revamped False Claims Act Working Group